Safety and efficacy of isocitrate dehydrogenase‐1 inhibitor ivosidenib in patients with cholangiocarcinoma

Documenti analoghi

• CEACAM6 silencing suppresses tumour growth and sensitises cholangiocarcinoma to cisplatin
  di: Shi‐Jia Dai, et al.
  Pubblicazione: (2026)
• CEACAM6: A potential prognostic biomarker and therapeutic target in cholangiocarcinoma
  di: Jia‐Qi Guo, et al.
  Pubblicazione: (2026)
• Platelet volume could predict the efficacy of thrombopoietin receptor agonists in the treatment of patients with primary immune thrombocytopenia
  di: Bei Xu, et al.
  Pubblicazione: (2025)
• Utilisation of a national database to characterise renal function in patients with COVID19 infection
  di: Nicholas R. Nelson, et al.
  Pubblicazione: (2025)
• Exporting nuclear export inhibitors from hematologic to solid tumour malignancies
  di: Alexandra Chirino, et al.
  Pubblicazione: (2024)